Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment...
31 KB (2,444 words) - 00:18, 6 August 2024
program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results...
13 KB (1,018 words) - 04:46, 6 July 2024
treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab. "Tremfya...
14 KB (1,037 words) - 04:45, 6 July 2024
urtoxazumab (INN) usistapide (USAN, INN) ustekinumab (USAN, INN) ustekinumab-aekn ustekinumab-auub ustekinumab-ttwe utibapril (INN) utibaprilat (INN) Uticillin...
4 KB (291 words) - 04:50, 2 July 2024
bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS". Therapeutic Goods...
11 KB (656 words) - 16:11, 7 August 2024
such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development of biological therapy as a modality to treat...
28 KB (3,327 words) - 19:25, 25 July 2024
received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023. Products under development include biosimilars of...
11 KB (914 words) - 20:13, 22 June 2024
Management of Crohn's disease (section Ustekinumab)
needed] Ustekinumab (CNTO 1275) is a monoclonal antibody that suppresses cytokines IL-12 and IL-23. Originally designed to treat psoriasis, ustekinumab was...
44 KB (4,607 words) - 00:50, 4 May 2024
share a common domain, p40, which is the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have...
116 KB (12,973 words) - 02:21, 16 August 2024
Armando; Moreira, Ana Isabel (2016-05-24). "Inverse psoriasis treated with ustekinumab". BMJ Case Reports. BMJ: bcr2016215019. doi:10.1136/bcr-2016-215019....
7 KB (611 words) - 16:36, 7 April 2024
antibodies, such as infliximab, adalimumab, certolizumab, vedolizumab, ustekinumab, natalizumab,risankizumab-rzaa, and upadacitinib Hydrocortisone should...
162 KB (18,417 words) - 20:04, 18 August 2024
certolizumab pegol and adalimumab, as well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab...
32 KB (3,438 words) - 14:55, 9 July 2024
disease ulcerative colitis ankylosing spondylitis inhibits TNF-α human ustekinumab Crohn's disease ulcerative colitis plaque psoriasis psoriatic arthritis...
49 KB (4,964 words) - 04:02, 9 August 2024
is one of the therapeutic targets to treat the inflammatory diseases. Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat...
20 KB (2,192 words) - 23:02, 27 November 2023
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (1,789 words) - 04:29, 16 July 2024
Japan for use in treating psoriatic arthritis. The anti-IL-23 antibody ustekinumab can also be used to effectively treat psoriasis by indirectly reducing...
35 KB (3,989 words) - 13:32, 13 July 2024
and Th17 T-cells. IL-12 and IL-23 signaling is blocked by the biologic ustekinumab and IL-23 is blocked by guselkumab, mirikizumab and risankizumab, medications...
142 KB (16,179 words) - 20:58, 26 July 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
17 KB (1,245 words) - 04:39, 17 August 2024
WANG, Ting-Shun; TSAI, Tsen-Fang (May 4, 2011). "Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series". The Journal...
22 KB (2,022 words) - 04:15, 7 August 2024
corticosteroids. There are also reports that the monoclonal antibody ustekinumab (which blocks IL-23/ IL-12) may be effective. List of cutaneous conditions...
5 KB (535 words) - 17:39, 6 January 2022
showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo. However, in May 2015, Amgen announced that it was ending...
9 KB (616 words) - 03:20, 14 August 2024
history, preferences, and the recommendations of the healthcare provider. Ustekinumab has frequently been used as a second-line therapy for AS, but it has...
56 KB (5,950 words) - 20:22, 8 July 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (2,581 words) - 20:03, 21 June 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
24 KB (2,070 words) - 07:13, 15 March 2024
results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis. In the same month, construction...
96 KB (7,734 words) - 22:23, 14 August 2024
factors csDMARD tocilizumab IL-6 receptor antagonist bDMARD tofacitinib Janus kinase (JAK) inhibitor tsDMARD ustekinumab IL-12 and IL-23 inhibitor bDMARD...
10 KB (869 words) - 20:47, 1 July 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
43 KB (3,662 words) - 19:35, 12 July 2024
breast cancer humanized monoclonal antibody HER2/neu (erbB2) antagonist ustekinumab Stelara psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease...
30 KB (2,882 words) - 11:11, 23 July 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
9 KB (587 words) - 20:04, 20 December 2023
Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab...
3 KB (367 words) - 15:37, 25 January 2024